Journal of Clinical Oncology
Articles in this Issue
Extended follow-up (6 years) of the phase 2 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease–associated neoplasms.
4550 Background: Belzutifan, a potent and selective hypoxia-inducible factor 2α inhibitor, is indicated for treatment of p...
Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
e15539 Background: Maintenance therapy with bevacizumab (Bev) plus capecitabine (Cap) is recommended to unresectable mCRC...
Mortality burden of hepatocellular carcinoma and diabetes in the United States, 1999–2023.
e16355 Background: Hepatocellular carcinoma (HCC) and diabetes mellitus are major contributors to morbidity and mortality...
Assessing the true burden of immune-related colitis in lung cancer through large language model–enabled clinical phenotyping.
1615 Background: Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment but cause adverse events, i...
Association of neighborhood-level vulnerability with health behavior patterns in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE).
10010 Background: Childhood cancer survivors face elevated risks for chronic health conditions and premature mortality. En...
Randomized phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus FTD/TPI for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma: Final analysis of RETRIEVE study (WJOG 15822G).
4038 Background: Promising activity of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) has been reported in single...
Association of prior prostate cancer screening with stage at diagnosis in a US EHR cohort, 2018–2025.
e17071 Background: The US Preventative Service Task Force recommends prostate-specific antigen (PSA)-based screening for m...
Plasma small extracellular vesicle microRNAs as non-invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma.
4227 Background: Current non-invasive approaches for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) exhibit inhe...
Role and mechanism of CMTM6 in radiosensitivity of breast cancer cells.
e12600 Background: To further investigate the role of CMTM6 in breast cancer radiosensitivity, this study employed lentivi...
Post-operative ctDNA-detected molecular residual disease in resected non-small cell lung cancer: A systematic review and meta-analysis of prognostic accuracy.
e20043 Background: Non-small cell lung cancer (NSCLC) continues to be the most common cause of cancer-related deaths globa...
Impact of population-specific <i>KRAS</i> alterations on therapeutic vulnerabilities in cholangiocarcinoma: Evidence from a global meta-analysis.
e16494 Background: Cholangiocarcinoma (CCA) exhibits marked molecular heterogeneity with significant geographic variation,...
Reporting of propranolol use in studies of beta-blockers in colorectal cancer.
e23378 Background: Beta-adrenergic blockers have been investigated for potential therapeutic and prognostic effects across...
Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: A real-world analysis.
e16383 Background: Metastatic pancreatic adenocarcinoma (mPDAC) is associated with poor prognosis and limited treatment op...
Elevated genomic risk and treatment gaps in Black patients with HR+ early breast cancer: A MammaPrint-based retrospective analysis.
e12766 Background: Black women with hormone receptor-positive (HR+) early-stage breast cancer (EBC) have a 38% higher mort...
Trends and disparities in mortality from malignant neoplasms and cardiac arrest in the United States, 1999–2023.
e23365 Background: Malignant neoplasms (MN) significantly heighten mortality risk when they co-occur with cardiac arrest (...
Middle-high altitude residence as a predictor of improved immune checkpoint inhibitor outcomes in advanced NSCLC: A multicenter cohort study.
e20597 Background: Immune checkpoint inhibitors (ICIs) have transformed treatment for advanced non-small cell lung cancer...
Immunologic determinants in procured melanoma tissue as drivers of durable response to tumor-infiltrating lymphocyte therapy.
9511 Background: Predictive biomarkers that identify melanoma tumors capable of generating therapeutically effective tumor...
Sequencing in the post-immunotherapy era: Does second-line tyrosine kinase inhibitor choice impact survival and safety in advanced HCC?
4140 Background: IMbrave150 trial established atezolizumab/bevacizumab as first line (1L) treatment for advanced hepatocel...
Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
6008 Background: Prognosis is poor for patients with HPV-unrelated recurrent/metastatic (R/M) head and neck squamous cell...
Randomized phase 3 study (MarsLight-11) evaluating IBI363 (TAK-928) versus docetaxel in patients (pts) with squamous non-small cell lung cancer (sqNSCLC) after prior chemotherapy (chemo) and immunotherapy (IO).
TPS8673 Background: In most series, sqNSCLC has worse clinical outcomes compared with non-squamous NSCLC with IO combinati...
Are lobectomy and neoadjuvant therapy the missing link in improving early-stage small cell lung cancer survival?
8077 Background: Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis. This study evaluates natio...
Incidence, survival, and persistent age and sex disparities in uveal melanoma: A SEER population study (2000–2022).
e21538 Background: It is unclear whether population-level incidence and survival for uveal melanoma have changed over time...
Spatial neighborhood effects and geographic embeddings in random forest modeling of mammography screening rates.
e13643 Background: Mammography screening rates vary geographically across the United States, yet standard machine learning...
Association of cardiovascular outcomes with GnRH agonist and antagonist therapy in non-metastatic prostate cancer.
5123 Background: Androgen deprivation therapy (ADT) is known to increase cardiometabolic risk. Randomized trials suggest G...
Time to treatment initiation and clinical, toxicity, and supportive care outcomes in multiple myeloma: A real-world Epic Cosmos analysis.
e19559 Background: Timely initiation of systemic therapy is critical in multiple myeloma (MM), yet real-world variation in...